{
    "Overall_score": {
        "Correlation": 7,
        "Sentiment": 6,
        "Importance": 7,
        "Impact": 6,
        "Duration": 5,
        "Virality": 4,
        "Source_Score": 6,
        "Specificity": 7,
        "Sector_Spread": 5,
        "Tech_Mentions": 3
    },
    "Each_item": [
        {
            "News_content": "RT @MarkSchoenebaum: says there were NO lab abnormalities in the all oral dosing arms (e.g. ALT). Will have details @ 5pm London time.",
            "Correlation": 9,
            "Sentiment": 8,
            "Importance": 8,
            "Impact": 7,
            "Duration": 6,
            "Virality": 5,
            "Source_Score": 8,
            "Specificity": 9,
            "Sector_Spread": 4,
            "Tech_Mentions": 2
        },
        {
            "News_content": "to continue to fade and fill in the gap",
            "Correlation": 5,
            "Sentiment": 4,
            "Importance": 3,
            "Impact": 4,
            "Duration": 3,
            "Virality": 2,
            "Source_Score": 3,
            "Specificity": 5,
            "Sector_Spread": 2,
            "Tech_Mentions": 1
        },
        {
            "News_content": "RT @MarkSchoenebaum: New Hep C data from are excellent: 1 pill/once per day cures 98% of patients. Analysts' estimates likely to rise",
            "Correlation": 10,
            "Sentiment": 9,
            "Importance": 9,
            "Impact": 8,
            "Duration": 7,
            "Virality": 6,
            "Source_Score": 8,
            "Specificity": 10,
            "Sector_Spread": 6,
            "Tech_Mentions": 3
        },
        {
            "News_content": "RT @hydrogenblimp no doubt is looking like #3 combo, lots of drug interactions, but in the end price will drive the train",
            "Correlation": 8,
            "Sentiment": 6,
            "Importance": 7,
            "Impact": 6,
            "Duration": 5,
            "Virality": 4,
            "Source_Score": 6,
            "Specificity": 8,
            "Sector_Spread": 5,
            "Tech_Mentions": 2
        },
        {
            "News_content": "Watch Idea - Gappers:  #stocks #trading #options  -r",
            "Correlation": 4,
            "Sentiment": 5,
            "Importance": 4,
            "Impact": 4,
            "Duration": 3,
            "Virality": 3,
            "Source_Score": 4,
            "Specificity": 4,
            "Sector_Spread": 3,
            "Tech_Mentions": 1
        },
        {
            "News_content": "Gilead Sciences, Inc. (NASDAQ:) To Face Completion From  & Co ...",
            "Correlation": 8,
            "Sentiment": 5,
            "Importance": 7,
            "Impact": 6,
            "Duration": 6,
            "Virality": 4,
            "Source_Score": 7,
            "Specificity": 8,
            "Sector_Spread": 6,
            "Tech_Mentions": 2
        },
        {
            "News_content": "RT @Loftus:  is in the race for next-generation Hepatitis C regimen   http://t.co/AjgGPbD9Ph",
            "Correlation": 9,
            "Sentiment": 7,
            "Importance": 8,
            "Impact": 7,
            "Duration": 6,
            "Virality": 5,
            "Source_Score": 7,
            "Specificity": 9,
            "Sector_Spread": 5,
            "Tech_Mentions": 3
        },
        {
            "News_content": "Our Penny Stock Newsletter Alerts gained 2,100% in 4 weeks! Huge News: http://t.co/0paInw1uTv #Breakout",
            "Correlation": 6,
            "Sentiment": 8,
            "Importance": 6,
            "Impact": 5,
            "Duration": 4,
            "Virality": 7,
            "Source_Score": 5,
            "Specificity": 6,
            "Sector_Spread": 3,
            "Tech_Mentions": 1
        }
    ]
}